Market Highlights
Nephroblastoma is the most common type of kidney cancer in children. The prevalence rate of nephroblastoma is about 9 out of 10 kidney cancers in children. Tumors which affects only one kidney and have only one tumor are unilateral. Around 5-10% of children with nephroblastoma have more than one tumor in the same kidney. About 5% of children with nephroblastoma have tumors in both kidneys which means they have bilateral disease.
Nephroblastoma often become large and occasionally some newly found nephroblastoma are larger than the kidney itself. Currently scenario indicates the survival rate of children suffering from nephroblastoma is approximately 80% to 90%.
Furthermore, macro-economic factors such as increasing expenditure on research and development to develop novel therapies for nephroblastoma will drive this market in forecast period. On the other hand, lack of skilled healthcare professionals, rich experience in using these advanced technologies, high cost associated with the diagnosis and treatment procedure are expected to act as a restrains to the nephroblastoma treatment market.
The global nephroblastoma treatment market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.
Regional Analysis
Global nephroblastoma treatment consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas hold the largest share of the global nephroblastoma treatment market owing to the growing incidence of kidney cancers in the U.S. The Europe is the second largest market for the nephroblastoma treatment market owing to the high prevalence rate of this disease in the Eastern European regions.
The Asia Pacific is expected to be the fastest growing region during the forecasted period 2017-2023. The incidence ratio of nephroblastoma is 1 in every 10,000 with 85% of patients usually younger than 6 years. The screening is usually performed on infants with age of 2-3 year. Girls are affected more than boys with different incidence for children of different ethnicities. For instance, the incidence rate in Asia is substantially lower than in European or American children.
Segmentation
The nephroblastoma treatment is segmented on the basis of types, drugs, diagnosis, treatment, distribution channel, and end-users. On the basis of the types, the market is segmented into favorable histology, unfavorable histology (anaplastic wilms tumor). On the basis of the drugs, the market is segmented into dactinomycin (cosmegen), doxorubicin (adriamycin), vincristine (vincasar pfs, oncovin), cyclophosphamide (cytoxan, neosar), etoposide (toposar, vepesid), irinotecan (camptosar), and others. On the basis of the diagnosis, the market is segmented into ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), chest x-ray, bone scan, lab tests and others.
On the basis of the treatment, the market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery is classified into radical nephrectomy, partial nephrectomy (nephron-sparing surgery), and others. On the basis of the distribution channel, the market is segmented into hospital pharmacies, e-commerce, drug stores, retail pharmacy, and others. On the basis of the end-user, the market is segmented into hospitals, cancer centers, surgical centers and ambulatory surgical center.
Key Players
Some of key the players in the global nephroblastoma treatment market are Bayer HealthCare LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi Pasteur Inc. (U.S.), Merck & Co. Inc. (U.S.), MediLexicon International Ltd (U.S.), Bristol-Myers Squibb Company (U.S.), Apotex Inc. (U.S.), and others.

Read More:https://www.marketresearchfuture.com/reports/nephroblastoma-treatment-market-5229